FDA Initiates Pilot Program to Expedite First-in-Human Clinical Trials

The U.S. FDA has finalized and launched its Expedited Investigational New Drug (IND) Pilot program. This initiative aims to significantly reduce the time from drug identification to the start of first-in-human clinical trials by fostering partnerships between drug companies and qualified research institutions. The FDA is currently accepting applications for participation until October 30, 2026. This program seeks to maintain American leadership in medical innovation and ensure patients gain quicker access to novel therapies.